DelveInsight has added a new research study on Hereditary Transthyretin Amyloidosis Market Report with detailed information on the overview, market insights, drugs industry, treatment, growth, size, share, trends, during the forecast period of 2017 to 2030
Hereditary Transthyretin Amyloidosis Overview
Transthyretin Amyloidosis (ATTR) is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body’s organs and tissues. ATTR is sub-classified as wild-type (wt) or hereditary; the latter is then further subdivided into familial amyloid polyneuropathy (FAP) and familial amyloid cardiomyopathy (FAC).
Download Sample Copy @ https://www.delveinsight.com/sample-request/hereditary-transthyretin-amyloidosis-competitive-landscape-and-market
Hereditary Transthyretin Amyloidosis Market: Regions Covered
List of Companies involved in Hereditary Transthyretin Amyloidosis Market Report–
Hereditary Transthyretin Amyloidosis Symptoms
hATTR amyloidosis involves many systems in the body and can result in a wide variety of symptoms, including sensory and motor, autonomic (e.g., diarrhea, hypotension, erectile dysfunction), and cardiac symptoms.
Hereditary Transthyretin Amyloidosis Market Disease
The disease continuum of hATTR amyloidosis encompasses patients who present with predominantly polyneuropathy symptoms (involving the nerves), known as familial amyloidotic polyneuropathy (FAP), and also patients who present with predominant cardiomyopathy symptoms (involving the heart), historically known as familial amyloidotic cardiomyopathy (FAC); however, many patients also experience gastrointestinal symptoms.
Hereditary Transthyretin Amyloidosis Diagnosis
Individuals affected by hATTR need an early and accurate diagnosis due to the potential progression of the disease. Misdiagnosis of hATTR is widespread because of its symptom’s commonality with that of numerous other diseases, giving rise to potentially ineffective or harmful treatment. Procedures commonly used to confirm the diagnosis of hATTR include blood tests, organ biopsies, and tissue biopsies.
Hereditary Transthyretin Amyloidosis Treatment
Current treatment options for patients with hATTR include some recently approved therapies, symptomatic treatment, and liver transplantation. Since TTR protein is mainly produced in the liver, transplanting a new liver should almost eliminate the production of variant protein and further halt the disease progression outside the brain and eyes.
Hereditary Transthyretin Amyloidosis Drugs
Recently few drugs are approved for the treatment of hATTR. The approved therapies include inotersen (Tegsedi), patisiran (Onpattro), tafamidis meglumine (Vyndaqel), and tafamidis (Vyndamax).
Hereditary Transthyretin Amyloidosis Market Insights
Patients with FAP usually die after 10–20 years post the onset of symptoms, and its symptoms are similar to numerous other diseases often leading to misdiagnosis; therefore, there is an immense need for early diagnosis, identification, and treatment of FAP for improving the patients’ quality of life
Hereditary Transthyretin Amyloidosis Market Outlook
The Hereditary Transthyretin Amyloidosis (hATTR) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Hereditary Transthyretin Amyloidosis (hATTR) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
Hereditary Transthyretin Amyloidosis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Hereditary Transthyretin Amyloidosis (hATTR) market or expected to get launched in the market during the study period 2017–2030. The analysis covers Hereditary Transthyretin Amyloidosis (hATTR) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Hereditary Transthyretin Amyloidosis Market Report Scope
Read Detailed Table of Content of Hereditary Transthyretin Amyloidosis Market Report
1 Key Insight
2 Executive Summary of hATTR
3 Hereditary Transthyretin Amyloidosis Market Overview at a Glance
3.1 Market Share (%) Distribution of Hereditary Transthyretin Amyloidosis in 2017
3.2 Market Share (%) Distribution of Hereditary Transthyretin Amyloidosis in 2030
4 Hereditary Transthyretin Amyloidosis (hATTR): Disease Background and Overview
5 Epidemiology and Patient Population
6 Current Treatment and Medical Practices
7 Unmet Needs
8 Marketed Drugs
9 Emerging Therapies
10 Phase III and Filed Drugs
11 Phase II Drugs
12 Phase I Drugs
13 Hereditary Transthyretin Amyloidosis: Market Analysis
14 Hereditary Transthyretin Amyloidosis (hATTR) Market Outlook
15 Market Drivers
16 Market Barriers
17 Reimbursement Scenario
18 Patient Support Programs
19 SWOT Analysis
20 KOL’s Views
21 Appendix
22 DelveInsight Capabilities
23 Disclaimer
24 About DelveInsight
Hereditary Transthyretin Amyloidosis Market Report Highlights
How Does This Hereditary Transthyretin Amyloidosis Market Insights Help?
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions
Media ContactCompany Name: DelveInsight Business ResearchContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/